Olema Pharmaceuticals, Inc.OLMA
What Olema Pharmaceuticals, Inc. does.
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Our lead product candidate, palazestrant (formerly known as OP-1250), is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), breast cancer. In pre-clinical models, palazestrant binds and completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer. In clinical studies across more than 400 patients, palazestrant has demonstrated strong anti-tumor activity, attractive pharmacokinetics and prolonged drug exposure, favorable tolerability, and combinability with cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) with no significant drug-drug interaction. Based on the clinical results we have achieved to date, we are advancing palazestrant through late-stage clinical development both as a monotherapy and in combination with other targeted agents.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Free cash flow | -$19.9M | -$52.3M | -$82.4M | — | -$104.5M | — |
More on OLMA.
- Olema Pharmaceuticals, Inc. summary
- Olema Pharmaceuticals, Inc. financial statements
- Olema Pharmaceuticals, Inc. key metrics
- Olema Pharmaceuticals, Inc. health scores and style box
- Olema Pharmaceuticals, Inc. earnings
- Olema Pharmaceuticals, Inc. dividends
- Olema Pharmaceuticals, Inc. valuation
- Olema Pharmaceuticals, Inc. ownership and insiders
- Olema Pharmaceuticals, Inc. peers
Figures from Olema Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.